Kodu・Aktsiate loetelu・GlaxoSmithKline PLC
Search

GlaxoSmithKline PLC

Suletud

SektorTervishoid

1,888 -1.44

Neutraalne

Hinna uuendus 29. mai 2026, 15:29 UTC

OstaMüü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1887.5

Max

1899.5

Põhinäitajad

By Trading Economics

Sissetulek

1.2B

1.8B

Müük

-989M

7.6B

P/E

Sektori keskmine

13.597

50.102

Aktsiakasum

0.465

Dividenditootlus

3.5

Kasumimarginaal

24.105

Töötajad

66,841

EBITDA

577M

2.8B

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

+10.68% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

3.50%

2.33%

Järgmine tulemuste avaldamine

28. juuli 2026

Järgmine dividendimakse kuupäev

9. juuli 2026

Järgmine aktsia dividendi kuupäev (ex-date)

13. aug 2026

Turustatistika

By TradingEconomics

Turukapital

-3B

77B

Eelmine avamishind

1889.44

Eelmine sulgemishind

1888

Uudiste sentiment

By Acuity

46%

54%

121 / 344 Pingereas Healthcare

GlaxoSmithKline PLC Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

29. apr 2026, 06:42 UTC

Tulu

GSK Earnings Boosted by Higher Specialty Medicine Sales

DJ

Loe

29. mai 2026, 09:17 UTC

Market Talk

GSK Hepatitis B Drug Data Beat Expectations -- Market Talk

DJ

Loe

6. mai 2026, 13:35 UTC

Market Talk

GSK Is Taking Steps in Right Direction, But Might Need More -- Market Talk

DJ

Loe

29. apr 2026, 10:39 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

GSK CEO Sees RAPT Therapeutics Acquisition as Template for Future Deals -- Market Talk

DJ

Loe

29. apr 2026, 10:06 UTC

Market Talk
Tulu

AstraZeneca, GSK Results Fail to Impress Market -- Market Talk

DJ

Loe

29. apr 2026, 10:02 UTC

Market Talk
Tulu

GSK Makes Ideal Start for New CEO -- Market Talk

DJ

Loe

29. apr 2026, 06:07 UTC

Tulu

GSK PLC Sees 70p 2026 Dividend Payout

DJ

Loe

29. apr 2026, 06:07 UTC

Tulu

GSK PLC Declares Dividend of 17p

DJ

Loe

29. apr 2026, 06:07 UTC

Tulu

GSK PLC Free Cash Flow of GBP0.8B

DJ

Loe

29. apr 2026, 06:06 UTC

Tulu

GSK PLC Cash Generated From Operations GBP1.4B

DJ

Loe

29. apr 2026, 06:06 UTC

Tulu

GSK PLC 1Q General Medicines Sales GBP2.3B

DJ

Loe

29. apr 2026, 06:06 UTC

Tulu

GSK PLC 1Q Vaccines Sales GBP2.1B

DJ

Loe

29. apr 2026, 06:06 UTC

Tulu

GSK PLC 1Q Specialty Medicines Sales GBP3.2B

DJ

Loe

29. apr 2026, 06:05 UTC

Tulu

Analysts Saw GSK PLC 1Q Net Profit at GBP1.74B

DJ

Loe

29. apr 2026, 06:04 UTC

Tulu

Analysts Saw GSK 1Q Adjusted Operating Profit of GBP2.46B

DJ

Loe

29. apr 2026, 06:04 UTC

Tulu

GSK PLC 1Q Adjusted Operating Profit GBP2.65B

DJ

Loe

29. apr 2026, 06:04 UTC

Tulu

Analysts Saw GSK PLC Core EPS of 43.3p

DJ

Loe

29. apr 2026, 06:04 UTC

Tulu

Analysts Saw GSK PLC 1Q Turnover at GBP7.58B

DJ

Loe

29. apr 2026, 06:04 UTC

Tulu

GSK PLC 1Q Adj EPS 46.50p

DJ

Loe

29. apr 2026, 06:01 UTC

Tulu

GSK PLC Sees 2026 Adjusted EPS Growth of 7%-9%

DJ

Loe

29. apr 2026, 06:01 UTC

Tulu

GSK PLC Sees 2026 Adjusted Oper Pft Growth of 7%-9%

DJ

Loe

29. apr 2026, 06:01 UTC

Tulu

GSK PLC Sees 2026 Turnover Growth of 3%-5%

DJ

Loe

29. apr 2026, 06:01 UTC

Tulu

GSK PLC Backs 2026 View

DJ

Loe

29. apr 2026, 06:00 UTC

Tulu

GSK PLC 1Q EPS 42.6p

DJ

Loe

29. apr 2026, 06:00 UTC

Tulu

GSK PLC 1Q Turnover GBP7.63B

DJ

Loe

29. apr 2026, 06:00 UTC

Tulu

GSK PLC 1Q Pretax Pft GBP2.14B

DJ

Loe

29. apr 2026, 06:00 UTC

Tulu

GSK PLC 1Q Oper Pft GBP2.29B

DJ

Loe

29. apr 2026, 06:00 UTC

Tulu

GSK PLC 1Q Net Pft GBP1.74B

DJ

Loe

15. apr 2026, 06:12 UTC

Omandamised, ülevõtmised, äriostud

GSK Completes Acquisition of 35Pharma

DJ

Loe

10. apr 2026, 10:43 UTC

Market Talk

GSK Could Report Weak General Medicines Results -- Market Talk

DJ

Loe

GlaxoSmithKline PLC Prognoos

Hinnasiht

By TipRanks

10.68% tõus

12 kuu keskmine prognoos

Keskmine 2,082.36 GBX  10.68%

Kõrge 2,630 GBX

Madal 1,700 GBX

Põhineb 14 Wall Streeti analüütiku instrumendi GlaxoSmithKline PLC 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

14 ratings

4

Osta

7

Hoia

3

Müü

Põhineb 14 analüütiku instrumendi GlaxoSmithKline PLC aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

121 / 344 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest GlaxoSmithKline PLC

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.
help-icon Live chat